Literature DB >> 186560

RNA synthesis in BHK 21 cells persistently infected with vesicular stomatitis virus and rabies virus.

L P Villarreal, J J Holland.   

Abstract

Virus-induced RNA synthesis was studied in BHK 21 cells persistently infected with vesicular stomatitis virus (VSV) and rabies virus by labelling RNA synthesized in the presence of antinomycin D. During persistent infection the species of messenger RNA synthesized were similar in size and relative proportions to those seen during acute infection, but there were some minor differences. Full-sized B virion RNA was generally not detected during persistent infection, and new species (probably DI virion RNA) appeared.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 186560     DOI: 10.1099/0022-1317-33-2-213

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Persistent vesicular stomatitis virus infection mediates base substitutions in viral RNA termini.

Authors:  B L Semler; J J Holland
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

2.  Persistent infection of a temperature-sensitive G31 vesicular stomatitis virus mutant in neural and nonneural cells: biological and virological characteristics.

Authors:  J Huprikar; S G Rabinowitz; M C DalCanto; M K Rundell
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

3.  A comparative study of tick-borne encephalitis virus RNA synthesis in acutely and persistently infected cells.

Authors:  O G Andzhaparidze; Y S Boriskin; I D Drynov; N N Bogomolova; N V Chelyapov
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

4.  Rabies mRNA translation in Xenopus laevis oocytes.

Authors:  W H Wunner; P J Curtis; T J Wiktor
Journal:  J Virol       Date:  1980-10       Impact factor: 5.103

5.  Quantitative analysis of defective interfering particles in infectious pancreatic necrosis virus preparations.

Authors:  R D Macdonald; T Yamamoto
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.